Therapeutic Effect Of Sequential Lobaplatin On Malignant Pleural Effusion In NSCLC Patients With Endostatin And IL-2

Objective To investigate the efficacy of sequential lobaplatin on malignant pleural effusion in non-small cell lung cancer patients with endostatin and IL-2,including the short-term efficacy,quality of life improvement and adverse reaction rate in the two groups..Methods 56 cases of non-small cell lung cancer and pleural effusion were randomly divided into group A and group B,and 28 patients in group A and group B.Group A was given recombinant human endostatin injection combined with lobaplatin for thoracic perfusion,and group B was given interleukin-2 combined with lobaplatin for thoracic perfusion.Both groups were administered once a week for 4 weeks.The short-term efficacy,quality of life improvement,adverse reaction rate of pleural effusion reduction in the two groups were evaluated.Collect the case information of all the patients,then use the SPSS 24.0 statistical software to analyze the data,and P < 0.05 is statistically significant.Result1.The recent clinical efficacy : The disease control rate(DCR)in the A and B group were 89.29% and 78.57%,it was not significantly different(P>0.05).The total effective rates(RR)were 71.43% and 42.86%,the difference was statistically significant(P<0.05).2.The quality of life improvement: the quality of life improvement rate in the A and B group were 64.29% and 35.71%,the difference was statistically significant(P <0.05).There was no significant difference in the stability rate and reduction rate between the two groups(P>0.05).3.Adverse reaction: for neutropenia,decrease of hemoglobin as well as white blood cells,and the impairment of liver and kidney function as well as gastrointestinal reactions there were no statistical differences(P>0.05)between two groups.Conclusion The research demonstrated that endostatin sequential lobaplatin in the treatment of non-small cell lung cancer with malignant pleural effusion can improve the patient's near-term clinical outcome and improve their quality of life and do not increase adverse effects like myelosuppression and the impairment of liver and kidney function and gastrointestinal reactions...